Drug Trial Radar · NCT07559175
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Aimmune Nestlé Health Science US R&D, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase/pancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration. Number of Participants: The aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention. Study Arms and Duration: The total study duration for each participant will be about 100 days (approximately 14 weeks), including: * A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration. * A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2. * An end of treatment/early discontinuation visit within approximately 7 days of the last study intervention dose. * An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration. Very low dose group: 10 mg NHS7108 (approximately 25,000 LU)/main meal and snack; 25,000 LU Zenpep/main meal and snack (50 mg NHS7108 \[approximately 125,000 LU\] per day; 125,000 LU Zenpep per day) Low dose group: 20 mg NHS7108 (approximately 50,000 LU)/main meal and 10 mg NHS7108 (approximately 25,000 LU)/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack (80 mg NHS7108 \[approximately 200,000 LU\] per day; 200,000 LU Zenpep per day) Medium dose group: 40 mg NHS7108 (approximately 100,000 LU)/main meal and 20 mg (approximately 50,000 LU) NHS7108/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack (160 mg \[approximately 400,000 LU\] NHS7108 per day; 400,000 LU Zenpep per day) High dose group: 60 mg NHS7108 (approximately 150,000 LU)/main meal and 30 mg NHS7108 (approximately 75,000 LU)/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack (240 mg NHS7108 \[approximately 600,000 LU\] per day; 600,000 LU Zenpep per day). The dose for participants \< 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU/kg/day.
Conditions
- Exocrine Pancreatic Insufficiency (EPI)
- Cystic Fibrosis (CF)
- Pancreatic Enzyme Abnormality
- Pancreatic Diseases
Interventions
NHS7108Drug
NHS7108 is the experimental drug. It is a recombinant, modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovorans and produced by fermentation of recombinant Escherichia coli. Unit dose strength: 10 mg (approximately 25,000 LU) per capsule.
Zenpep®Drug
Zenpep® is the active comparator. It is a combination of lipases, proteases, and amylases. Unit dose strength: 25,000 LU per capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Objectives: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14 days after NHS7108 Treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: At screening and end-of-study/safety follow-up visit. A brief symptom-directed physical examination may be performed at all other visits and at any time throughout the study, as clinically indicated.
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment.
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14 -day after NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: Serum Beta-HCG pregnancy test (mIU/mL) (at screening) and urine pregnancy tests (at all other timepoints) as needed for women of childbearing potential.
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: Will be performed at screening in women with unconfirmed reproductive potential status only (to confirm postmenopausal state).
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safetyTime frame: 14 days after NHS7108 Treatment
- Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safetyTime frame: After 14 days NHS7108 treatment
Locations
39 sites in 7 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Not yet recruiting
University of Arkansas for Medical Sciences Hospital - University
Little Rock, Arkansas · Not yet recruiting
Keck Hospital of USC
Los Angeles, California · Not yet recruiting
Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr
Los Angeles, California · Not yet recruiting
Omnicure Clinical Research
Doral, Florida · Not yet recruiting
Advent Health Medical Group
Orlando, Florida · Not yet recruiting
Johnson County Clin-Trials (JCCT)
Lenexa, Kansas · Recruiting
Johns Hopkins Medicine - Pulmonary and Critical Care
Baltimore, Maryland · Not yet recruiting
Billings Clinic Hospital - Public
Billings, Montana · Not yet recruiting
University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital
Cleveland, Ohio · Not yet recruiting
The Ohio State University College of Medicine (OSUCOM)
Columbus, Ohio · Not yet recruiting
University of Oklahoma Health Sciences Center - Pediatrics Hospital - University
Oklahoma City, Oklahoma · Not yet recruiting
Penn State Health
Hershey, Pennsylvania · Recruiting
Vanderbilt University Medical Center - Pulmonary Hospital - University
Nashville, Tennessee · Not yet recruiting
Medical Center Medconsult Pleven, Lovech branch
Lovech, Bulgaria · Not yet recruiting
Medical Center Medconsult Pleven
Pleven, Bulgaria · Not yet recruiting
MC Hipokrat-N - Gastroenterology
Plovdiv, Bulgaria · Not yet recruiting
Medical Center Excelsior base 3
Sofia, Bulgaria · Not yet recruiting
MH Egészségügyi Központ - Gasztroenterológiai Osztály
Budapest, Hungary · Not yet recruiting
Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly
Budapest, Hungary · Recruiting
Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika
Csongrád, Hungary · Recruiting
Azienda Ospedaliero Universitaria Careggi - Gastroenterologia
Florence, Italy · Not yet recruiting
IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica
Milan, Italy · Not yet recruiting
Azienda Ospedaliera Universitaria Sant'Andrea
Roma, Italy · Not yet recruiting
AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public
Catania, Catania, Italy · Not yet recruiting
Humanitas Research Hospital
Rozzano, Lombardy, Italy · Not yet recruiting
Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic
Messina, Messina, Italy · Not yet recruiting
Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi
Lodz, Łódź Voivodeship, Poland · Not yet recruiting
WIP Warsaw IBD Point Profesor Kierkus
Pomorskie, Warszawa, Poland · Not yet recruiting
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Spain · Recruiting
H. General de Málaga - Endocrinología
Málaga, Spain · Recruiting
Hospital Universitario y Politecnico La Fe - Neumología
Valencia, Spain · Recruiting
Hospital Clinic De Barcelona - Cirug-ía General y Digestiva
Madrid, Barcelona, Spain · Not yet recruiting
Hospital Universitario La Paz Hospital - University
Madrid, Madrid, Spain · Not yet recruiting
Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA)
Murcia, Murcia, Spain · Not yet recruiting
Greater Glasgow and Clyde
Glasgow, United Kingdom · Not yet recruiting
The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom · Not yet recruiting
Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom · Not yet recruiting
Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice
Belfast, Northern Ireland, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.